BioMimetics Inc.

Cambridge, MA, United States

BioMimetics Inc.

Cambridge, MA, United States
SEARCH FILTERS
Time filter
Source Type

Christensen kommt zu SAB mit jahrzehntelanger Erfahrung auf dem Gebiet globaler Geschäftsstrategien und deren Umsetzung, die er als vormaliger Chief Financial Officer von Novo A/S erworben hat. Dieses in Dänemark ansässige Unternehmen verwaltet und investiert die Vermögenswerte der Novo Nordisk Foundation, deren Wert sich auf 40 Mrd. US-Dollar beläuft. Er war zudem mehr als zwei Jahrzehnte an der Etablierung der Organisationen von Novo Nordisk rund um den Erdball beteiligt – als CEO für China und Vice President of International Operations. Gegenwärtig ist Christensen als Berater für Novo A/S und als ein professionelles Mitglied des Boards u. a. der Strategic Design Group sowie von Sonion A/S tätig. Seit 2009 hatte er weitere Aufsichtsratspositionen privater sowie börsennotierter Unternehmen in Dänemark und im Ausland sowie in öffentlichen Institutionen inne, unter anderem die des Aufsichtsratsvorsitzenden im Dänisch-Chinesischen Forum, bei Jørgen Kruuse A/S und BioMimetics Inc, USA. SAB Biotherapeutics Inc. (SAB) ist ein auf der klinischen Stufe aktives biopharmazeutisches Entwicklungsunternehmen, das führend in der Wissenschaft und der Herstellung von Antikörpertherapeutika ist. Unter Nutzung fortschrittlichster wissenschaftlicher Erkenntnisse über polyklonale Antikörper stellt SAB die erste Plattform der Welt bereit, mit der sich in großem Maßstab vollständig menschliche Immunglobuline herstellen lassen. Diese natürliche Produktionsplattform verspricht die Behandlung von Problemen im Bereich der öffentlichen Gesundheit, seltenen Leiden, langfristigen Erkrankungen und Gefahren durch globale Pandemien.


M. Christensen apporte à SAB des décennies d'expérience en termes de stratégie et d'exécution commerciale à l'échelle mondiale, ayant auparavant occupé le poste de directeur financier pour la société Novo A/S basée au Danemark, qui investit et gère les actifs de la Fondation Novo Nordisk dont la valeur représente environ 40 milliards USD. Au cours de deux décennies, il a également créé des organisations Novo Nordisk dans le monde entier - notamment en tant que PDG pour la région Chine et en tant que vice-président des opérations internationales. « La technologie de SAB constitue une plateforme pour le développement de médicaments meilleurs et plus efficaces dans de nombreux domaines où les besoins ne sont pas satisfaits, » a déclaré Thorkil Kastberg Christensen. « C'est le principe de base de ce que j'ai fait pendant presque toute ma vie et je suis heureux de pouvoir apporter ma contribution, » a-t-il ajouté. Actuellement, M. Christensen est conseiller pour Novo A/S et membre professionnel des conseils d'administration de Strategic Design Group et de Sonion A/S, entre autres. Depuis 2009, il a occupé divers autres postes au sein de conseils d'administration pour des sociétés privées et publiques au Danemark, à l'étranger ainsi que pour des institutions publiques. Il est notamment le président du conseil d'administration du Forum d'affaires Danemark-Chine, de Jørgen Kruuse A/S et de BioMimetics Inc. aux États-Unis. « M. Christensen s'est avéré un conseiller de confiance et un atout pour SAB, au fur et à mesure que nous avons fait progresser notre technologie et développé des collaborations aux États-Unis et à travers le monde, » a déclaré Eddie Sullivan, Ph.D., président et chef de la direction de SAB Biotherapeutics. « Son expérience en matière de financement et de déploiement technologique et le réseau qu'il a mis en place avec des organisations de premier plan de santé publique, de biotechnologie et de l'industrie pharmaceutique, seront utiles au conseil, à l'heure où nous continuons à développer notre empreinte et notre portefeuille, » a-t-il ajouté. En tant que leader éminent dans le domaine des sciences de la vie, M. Christensen s'est spécialisé dans l'internationalisation, ainsi que dans les fusions et acquisitions et autres transactions. Son travail a consisté à créer des organisations et transformer des entreprises en se concentrant sur la R&D ou l'aspect commercial, ainsi qu'à valoriser des entreprises en croissance. « Les possibilités d'utiliser des anticorps humains, et des polyclonaux en particulier, pour le bénéfice de l'humanité sont infinies et dans de nombreux domaines, les potentiels commerciaux sont excellents, » a déclaré M. Christensen. « Je suis impatient de collaborer étroitement avec mes collègues de SAB et d'essayer de concrétiser certains de ces potentiels. » SAB développe actuellement des produits pour diverses cibles, dont la grippe saisonnière, le mycoplasme, la colite pseudomembraneuse, le virus Zika et le virus Ebola. En outre, un essai clinique de phase I réalisé en collaboration avec les Instituts nationaux de santé (National Institutes of Health) pour le traitement de la société contre le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV) est presque terminé et va bénéficier d'un soutien financier de la part de BARDA pour la Phase 2. SAB Biotherapeutics, Inc. (SAB) est une société de développement biopharmaceutique de stade clinique, leader dans la recherche et la fabrication de traitements à base d'anticorps. Utilisant la science des anticorps polyclonaux la plus avancée au monde, SAB possède la première plateforme à grande échelle au monde permettant de créer des immunoglobulines entièrement humaines. Cette plateforme de production naturelle pourrait permettre de traiter des problèmes de santé publique, des maladies rares, des maladies à long terme et des menaces de pandémie mondiale.


PubMed | Hannover Medical School, Colibri Photonics GmbH, BioMimetics Inc. and University of Toronto
Type: Journal Article | Journal: BioResearch open access | Year: 2015

We present a new method for noninvasive real-time oxygen measurement inside three-dimensional tissue-engineered cell constructs in static and dynamic culture settings in a laminar flow bioreactor. The OPAL system (optical oxygen measurement system) determines the oxygen-dependent phosphorescence lifetime of spherical microprobes and uses a two-frequency phase-modulation technique, which fades out the interference of background fluorescence from the cell carrier and culture medium. Higher cell densities in the centrum of the scaffolds correlated with lower values of oxygen concentration obtained with the OPAL system. When scaffolds were placed in the bioreactor, higher oxygen values were measured compared to statically cultured scaffolds in a Petri dish, which were significantly different at day 1-3 of culture. This technique allows the use of signal-weak microprobes in biological environments and monitors the culture process inside a bioreactor.


PubMed | Hannover Medical School, Colibri Photonics GmbH, BioMimetics Inc., Habsburger Allee 56 B and 8 Selden Street
Type: | Journal: BioMed research international | Year: 2015

A three-dimensional computational fluid dynamics- (CFD-) model based on a differential pressure laminar flow bioreactor prototype was developed to further examine performance under changing culture conditions. Cell growth inside scaffolds was simulated by decreasing intrinsic permeability values and led to pressure build-up in the upper culture chamber. Pressure release by an integrated bypass system allowed continuation of culture. The specific shape of the bioreactor culture vessel supported a homogenous flow profile and mass flux at the scaffold level at various scaffold permeabilities. Experimental data showed an increase in oxygen concentration measured inside a collagen scaffold seeded with human mesenchymal stem cells when cultured in the perfusion bioreactor after 24 h compared to static culture in a Petri dish (dynamic: 11% O2 versus static: 3% O2). Computational fluid simulation can support design of bioreactor systems for tissue engineering application.


PubMed | Shinyurigaoka General Hospital, BioMimetics Inc., University of Alabama at Birmingham and Sunfield Clinic
Type: Journal Article | Journal: PloS one | Year: 2016

It has been shown that adipose-derived mesenchymal stem cells (AMSCs) can differentiate into adipocytes, chondrocytes and osteoblasts. Several clinical trials have shown the ability of AMSCs to regenerate these differentiated cell types. Age-associated dysregulation of the gastrointestinal (GI) immune system has been well documented. Our previous studies showed that impaired mucosal immunity in the GI tract occurs earlier during agingthan is seen in the systemic compartment. In this study, we examined the potential of AMSCs to restore the GI mucosal immune system in aged mice. Aged (>18 mo old) mice were adoptively transferred with AMSCs. Two weeks later, mice were orally immunized with ovalbumin (OVA) plus cholera toxin (CT) three times at weekly intervals. Seven days after the final immunization, when fecal extract samples and plasma were subjected to OVA- and CT-B-specific ELISA, elevated levels of mucosal secretory IgA (SIgA) and plasma IgG antibody (Ab) responses were noted in aged mouse recipients. Similar results were also seen aged mice which received AMSCs at one year of age. When cytokine production was examined, OVA-stimulated Peyers patch CD4+ T cells produced increased levels of IL-4. Further, CD4+ T cells from the lamina propria revealed elevated levels of IL-4 and IFN- production. In contrast, aged mice without AMSC transfer showed essentially no OVA- or CT-B-specific mucosal SIgA or plasma IgG Ab or cytokine responses. Of importance, fecal extracts from AMSC transferred aged mice showed neutralization activity to CT intoxication. These results suggest that AMSCs can restore impaired mucosal immunity in the GI tract of aged mice.


Strauss S.,Hannover Medical School | Dudziak S.,Laser Zentrum Hannover e.V. | Hagemann R.,Laser Zentrum Hannover e.V. | Barcikowski S.,Laser Zentrum Hannover e.V. | And 8 more authors.
PLoS ONE | Year: 2012

The development of large tissue engineered bone remains a challenge in vitro, therefore the use of hybrid-implants might offer a bridge between tissue engineering and dense metal or ceramic implants. Especially the combination of the pseudoelastic implant material Nitinol (NiTi) with adipose derived stem cells (ASCs) opens new opportunities, as ASCs are able to differentiate osteogenically and therefore enhance osseointegration of implants. Due to limited knowledge about the effects of NiTi-structures manufactured by selective laser melting (SLM) on ASCs the study started with an evaluation of cytocompatibility followed by the investigation of the use of SLM-generated 3-dimensional NiTi-structures preseeded with ASCs as osteoimplant model. In this study we could demonstrate for the first time that osteogenic differentiation of ASCs can be induced by implant-mediated mechanical stimulation without support of osteogenic cell culture media. By use of an innovative implant design and synthesis via SLM-technique we achieved high rates of vital cells, proper osteogenic differentiation and mechanically loadable NiTi-scaffolds could be achieved. © 2012 Strauß et al.


Israelowitz M.,BioMimetics Inc. | Kwon J.-A.,Hillman Cancer Center | Rizvi S.W.H.,BioMimetics Inc. | Gille C.,Charité - Medical University of Berlin | And 2 more authors.
Journal of Bionic Engineering | Year: 2011

The Melanophila acuminata beetle is attracted to forest fires via a pair of infrared sensory organs composed of sensilla. Our histological work showed that each sensillum contains lipid layers surrounding a protein layer and a unique polysaccharide base that is associated with a neuron to each sensillum. Infrared microscopy showed that the protein region maximally absorbs infrared radiation at 3 μm wavelength and at 10 μm, which corresponds to the known radiation produced by forest fires at 3 μm. Mathematical calculations showed that the physical properties of the sensilla are such that the expected temperature rise is insufficient for transduction of the infrared signal through mechanical means or as a thermal receptor as previously thought; hence the protein plays the pivotal role in perception of single photons and transmission of the signal within the sensilla. © 2011 Jilin University.


Wu G.,University of Vermont | Xue S.,BioMimetics Inc.
IFMBE Proceedings | Year: 2010

Advanced age is often associated with an increased risk of accidental falls. Injuries such as hip fractures as a result of accidental falls in the elderly often lead to functional impairment, declined health, and loss of independence [1]. Fall-related hip fractures may be prevented by hip protection pads [2]. However, currently available hip pads are not widely accepted by elders because of cosmetic and comfort reasons [3]. Alternatively, an active protection apparatus - an airbag-based smart hip pad - would provide both an effective protection against the large impact when a fall occurs and the attractive cosmetic look when not sustaining a fall [4, 5]. One of the critical elements of the smart hip pad is the automated fall detection mechanism. The goals of this study were to (1) examine and distinguish the kinematic characteristics of impending falls from those of routine physical activities, and (2) develop a single sensor system to reliably detect falls before the impact occurs. It was hypothesized that the inertial frame vertical velocity near the body center of gravity would be significantly higher during the pre-impact phase of falls than regular daily activities, and that a single inertial sensor would be able to distinguish an in-progress and unrecoverable fall from non-falling activities. © 2010 International Federation for Medical and Biological Engineering.


The invention relates to a Microchip for the detection of poor sources of electrical and/or magnetic fields. To detect such poor electrical sources hidden in a body is a difficult problem for which was found a solution by this invention. The invention solves this problem by a Microchip consisting of a plate (1) with parallel rows of recesses (2), in each recess is a cristal (3) with a magnetic activity, between the rows are one or more wires (4,7) connected with a voltage source (9) and one or more wires connected with a voltmeter (6), the whole surface of the plate with the cristals in the recesses and the wires is embeded in a layer of semiconducting polimeres.


Patent
BioMimetics Inc. and Medizinische Hochschule Hanover | Date: 2011-10-04

The invention provides a process for producing a three-dimensional tissue by cultivating eucaryotic cells by introducing the cells into a matrix and cultivating the cells within the matrix in a cell culture medium within a cell culture vessel under controlled dissolved oxygen conditions of the cell culture medium. The matrix contains a support containing an optical oxygen sensor, which is an oxygen-sensitive dye, which upon irradiation with an excitation wavelength changes its emission characteristics in dependence on the dissolved oxygen concentration in the surrounding medium, including a dye phosphorescing upon irradiation of an excitation wavelength, which phosphorescence is quenched by dissolved oxygen.

Loading BioMimetics Inc. collaborators
Loading BioMimetics Inc. collaborators